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ABSTRACT 
Obesity is one of the diagnostic criteria of metabolic syndrome (MS). It is correlated with insulin resistance (IR) 
and high vascular risk as well. Advanced glycation end products (AGEs) and their receptor (RAGE) play an im-
portant role in abnormal metabolic components in obese women. This study aimed to explore the serum levels of 
sRAGE in Egyptian obese women and compare with healthy non-obese controls and investigate the relationship 
between serum sRAGE, metabolic parameters, and obesity complications. The soluble form of receptor for ad-
vanced glycation end products (sRAGE), anthropometry, metabolic and biochemical biomarkers were measured 
in 100 obese women and 100 age-matched healthy control non-obese women. The homeostasis model assessment 
estimate of insulin resistance (HOMA-IR) has been determined from serum insulin and glucose values. Serum 
sRAGE levels were significantly lower in obese cases than controls and inversely correlated with obesity and 
metabolic parameters. Results of univariate and multivariate analyses for determinants of serum sRAGE levels in 
obese cases showed that parameters statistically and significantly related were body mass index (BMI), waist cir-
cumference (WC), LDL-C, TG, BP, HOMA-IR, ALT and AST. sRAGE is a novel biomarker for metabolic dys-
function in Egyptian obese women and might predict the future cardio-metabolic events. 
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INTRODUCTION 
Metabolic syndrome along with its all 
clinical manifestations is highly associated 
with the development of chronic diseases. 
Advanced glycation end products (AGE) are 
formed by non-enzymatic glycoxidation of 
proteins and peptides after exposure to aldose 
sugars (Schmidt et al., 1994; Singh et al., 
2001). AGEs accumulate in the vessel walls 
and cause alteration of the extracellular ma-
trix, cell surface receptors, or could even af-
fect the function of intracellular proteins 
(Singh et al., 2001). Interactions between 
AGE and its receptors (RAGE) provoke oxi-
dative stress and stimulate pro-inflammatory 
or pro-coagulant cellular responses that com-
prising increases in the vascular cell adhesion 
molecule-1 and tumor necrosis factor-alpha 
expression (Brownlee, 1995). 
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RAGE is a multiligand receptor of the im-
munoglobulin superfamily that employs di-
verse ligands relevant to the pathogenesis of 
atherosclerosis (Koyama et al., 2005, 2007). 
RAGE has a C-truncated secreted isoform, 
designated soluble RAGE (sRAGE). In con-
trast to the cell surface RAGE, sRAGE is act-
ing as a decoy where it blocks cell surface 
RAGE ligand binding and its consequent sig-
naling (Hudson et al., 2005). Reduced levels 
of sRAGE have been described as an im-
portant novel biomarker in patients with hy-
pertension, type 2 diabetes, and also in non-
diabetic subjects with coronary artery disease 
(Geroldi et al., 2005; Falcone et al., 2005). 
Some studies have also determined that levels 
of plasma sRAGE are negatively associated 
with the components of MS, body mass index 
(BMI), waist-to-hip ratio, serum triglycerides 
(TG), systemic arterial pressure, and insulin 
resistance index in the adult population 
(Koyama et al., 2005; Norata et al., 2009). 
Accordingly, sRAGE, obesity, and MS are 
strongly associated with atherosclerosis. The 
progression of atherosclerosis commences 
during adolescence or even earlier, however, 
few studies have examined the relationship 
between sRAGE, obesity, and MS among ad-
olescents (He et al., 2014). In adults, an incon-
sistency has been observed between studies 
that examined the relation between sRAGE 
and metabolic syndrome components 
(Yamagishi et al., 2006; Norata et al., 2009; 
Hudson et al.,  2014). Hence, our study en-
rolled 100 obese women and 100 non-obese 
women to investigate the relationship be-
tween serum sRAGE, metabolic parameters 
and obesity complications. 
 
METHODS 
Subjects 
One hundred obese women between ages 
of 18 and 35 years were recruited from the 
obesity clinic, National Research Centre. 
None of the study participants had diabetes 
according to the criteria of American Diabetes 
Association (Puavilai et al., 1999). We ex-
cluded women who smoked cigarettes, taking 
medication that affect lipids or hormones, 
with cardiovascular disease or chronic kidney 
or liver disease, pregnant or breastfeeding, or 
had any other major illness. One hundred age-
matched healthy non-obese women are in-
cluded in the present study as a control group. 
Written informed consent was gained from 
each woman after a complete description of 
the study. The research has been authorized 
by the Ethical Committee of National Re-
search Centre, Egypt (number = 16361), in 
accordance with the World Medical Associa-
tion’s Declaration of Helsinki.  
 
Statistical analysis 
We performed the statistical analyses us-
ing SPSS16.0 for Windows (SPSS Inc). The 
distribution of the variables was examined us-
ing Kolmogorov–Smirnov test of normality to 
verify whether it is followed a Gaussian pat-
tern. Means ± SDs were used in order to ex-
press the normally distributed data, while log-
arithmic transformation was performed to all 
skewed variables. These variables, including 
triglycerides, fasting plasma glucose, and se-
rum sRAGE levels, were presented as median 
and interquartile ranges. The unpaired t-test 
or the Mann–Whitney U test was used, as ap-
propriate, to evaluate differences between the 
two groups of continuous variables. Categor-
ical variables are presented by frequency 
counts, and intergroup comparisons were an-
alyzed by a chi-square test. Simple (univari-
ate) and multiple (multivariate) logistic re-
gression analyses were performed to deter-
mine the associations between studied param-
eters and MS. Two-tailed P<0.05 was consid-
ered statistically significant. 
 
Clinical and biochemical assessment 
All patients and controls were subjected to 
full medical history and clinical examination. 
BMI has been determined as weight in kilo-
grams divided by height in meters square 
(kg/m2). Waist circumference (WC) and hip 
circumference (HC) have been measured in 
cm using a plastic, non-stretchable tailor’s 
tape. Subsequently, the Waist-to-Hip-Ratio 
(WHR) was calculated as WC divided by HC. 
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Skin-fold thickness was measured in all sub-
jects at the biceps, triceps, subscapular, supra-
iliac, and abdominal areas using Holtain cali-
per then, the sum of skin folds was calculated. 
A full description of the anthropometric 
measurements has been reported elsewhere 
(Zaki et al., 2015). All measurements were 
obtained according to standardized equip-
ment and following the recommendations of 
the International Biological Program 
(Hiernaux and Tanner, 1969). Body fat % was 
assessed by Tanita Body Composition Ana-
lyzer (SC-330). 
Blood pressure was measured according 
to a standardized operating procedure using 
calibrated sphygmomanometer and brachial 
inflation cuff (HEM-7200 M3, Omron 
Healthcare, Kyoto, Japan). Systolic and dias-
tolic blood pressures (SBP and DBP) were 
measured twice in the right arm in a sitting 
position after a 10-min rest period, then the 
average is used for analysis. Hypertension 
was defined as SBP ≥ 130 mmHg and/or DBP 
≥ 85 mmHg or the use of antihypertensive 
medications. 
 
Laboratory measurements 
Venous blood samples were collected by 
direct venipuncture after an overnight fast 
(minimum 12 h). Fasting plasma glucose and 
serum lipids (total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), triglycer-
ides (TG) were measured by enzymatic color-
imetric methods using a Hitachi auto-analyzer 
704 (Roche Diagnostics, Switzerland) 
(Hirschler et al., 2010). Low density lipopro-
tein cholesterol (LDL-C) was calculated ac-
cording to certain equation (LDL-C= Total 
cholesterol –Triglycerides/5+HDL-C). Serum 
insulin concentration was analyzed by chem-
iluminescent immunoassay (Immulite 2000, 
Siemens, Germany) (Chu et al., 2006). Insulin 
resistance has been estimated by the Homeo-
stasis Model Insulin Resistance (HOMA-IR); 
as the outcome of  fasting plasma insulin level 
(IU/mL) and fasting plasma glucose level 
(mmol/L) divided by 22.5 (Matthews et al., 
1985). Serum sRAGE was measured using a 
commercially available Quantikine ELISA 
kit (R&D System, Inc., Minneapolis, MN). 
 
RESULTS 
The basic characteristics of the study par-
ticipants are shown in Table 1. The concen-
tration of serum sRAGE was significantly 
lower in obese cases than in controls. In addi-
tion, the obese patients had significantly 
higher levels of BMI, WC, WHR, BP levels, 
ALT, AST, total cholesterol, TG, LDL and 
HOMA-IR (p<.05). 
 
Table 1: Clinical characteristics of obese women 
and control subjects 
Characteris-
tics
Obese Controls 
Age (years) 31.8±4.8 32.3±4.3 
BMI (kg/m2) 30.24±5.5* 25.24±4.2 
MUAC (cm) 30.5±8.1 29.9±6.2 
WC (cm) 96.2±8.15** 80.7±5.2 
WHR .83±.8* .73±.6 
Sum SF 148.5±27.9 144.1±22.3 
Body fat % 32.8±9.6 25.5±8.4 
SBP (mmHg) 135.8±10.7* 100.3±9.4 
DBP (mmHg) 85.8±7.9* 65.24±8.8 
HOMA-IR 6.7±1.2* 3.8±1.3 
FFG (mg/dL) 100.4±24.7 81.0±21.1 
ALT (IU/L) 37.3±28.1* 20.34±18.55 
AST (IU/L) 39.1±19.4* 21.1±18.1 
TC (mg/dL) 189.3±56.2* 119.6±26.1 
TG (mg/dL) 145.8  
(120-148.7)* 
105.2  
(100-118) 
HDL (mg/dL) 45.6±4.9 48.84±13.7 
LDL (mg/dL) 163 (89–140)* 113 (81–130) 
sRAGE 
(pg/mL)
955  
(658–1379)** 
1435  
(996–1956) 
BMI: body mass index; MUAC: mid upper arm circumference; 
WC: waist circumference; WHR: Waist-to-Hip-Ratio; Sum SF: 
sum of skin folds; SBP: systolic blood pressure; DBP: diastolic 
blood pressure; HOMA-IR: homeostasis model assessment-
insulin resistance; FPG: fasting plasma glucose; ALT: alanine 
aminotransferase; AST: aspartate aminotransferase; TC: total 
cholesterol; TG: triglycerides; HDL-C: high density lipoprotein 
cholesterol; LDL-C: low density lipoprotein cholesterol; 
sRAGE: soluble form of receptor for advanced glycation end 
products 
Data are mean±SD, median (interquartile range) 
*p<.05; ** p<.001 
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We further analyzed the clinical and an-
thropometric parameters of obese women by 
quartiles of serum sRAGE levels (Table 2). 
The mean concentration of sRAGE was 
1.355±505 pg/ml while it was <557 pg/ml for 
the lower quartile. Subjects in the lower quar-
tile serum sRAGE showed significant higher 
values of BMI, WC, SBP, DBP, HOMA-IR, 
total cholesterol, TG and LDL-C, ALT and 
AST compared to the highest quartile.  
Table 3 shows univariate and multiple lo-
gistic regression analysis. Univariate analysis 
revealed that BMI, waist circumference, SBP, 
DBP, HOMA-IR, LDL-C,TG, ALT and AST 
were inversely associated with serum levels 
of sRAGE in obese women. After performing 
multivariate analyses, these parameters still 
remained significant and were independently 
related to serum levels of sRAGE including 
BMI > 30 (kg/m2),WC > 90 cm, hypertension, 
HOMA-IR > 3.3, LDL-C, TG, ALT and AST 
(R2 = 0.294). 
DISCUSSION 
In this study, we demonstrated that serum 
levels of sRAGE were associated with meta-
bolic risk markers such as hypertension, cen-
tral obesity and elevated lipid parameters 
among Egyptian obese women. Furthermore, 
an inverse relationship between sRAGE and 
HOMA-IR was also observed. The findings 
of our study are partially in agreement with a 
previous study (Norata et al., 2009), in which 
sRAGE was found to be inversely associated 
with BMI and waist-to-hip ratio, no associa-
tion with metabolic syndrome has been no-
ticed though. According to the results of 
Norata and colleagues (2009), the level of 
plasma sRAGE might reflect the disturbed 
metabolic status that could later cause vascu-
lar complications and diabetes preceding to 
any of the clinical complication. The results  
 
Table 2: Clinical and anthropometric parameters of obese women, stratified according to quartiles of 
circulating sRAGE concentrations 
sRAGE (pg/ml) 
Characteristics Q1 
 
Q2 
 
Q3 
 
Q4 
 
 ≤557 558-899 900-1322 > 1322 
Age (years) 31.1±4.8 32.5±3.2 33.5±3.5 31.2±4.1 
BMI (kg/m2) 35.9±4.23* 32.5±6.9 29.4±5.6 24.8±7.4 
MUAC (cm) 33.2±15.9 31.7±16.2 32.6±17.4 31.3±15.5 
WC (cm) 96.4±10.9* 87.4±9.4 86.4±11.1 85.0±10.8 
WHR 0.9±.8 0.8±.4 0.8±.6 0.7±.5 
Sum SF 138.4±16.9 134.7±17.5 133.2±14.0 130.6±10.5 
Body fat % 40.5±12.8 36.4±10.8 39.6±11.9 37.4±9.8 
SBP (mmHg) 150.3±11.4* 128.4±9.3 125.4±9.3 110.1±10.5 
DBP (mmHg) 89.9±8.2* 77.3±7.4 75.3±6.8 70.5±8.6 
HOMA-IR 5.5±1.2* 3.3±.9 3.7±.7 3.4±1.1 
ALT(IU/L) 50±22.3 * 33.9±19.8 25.9±14.5 22.6±11.8 
AST (IU/L) 27.7±12.2* 22.6±5.9 22.6±5.9 20.7±15.1 
FPG (mg/dL) 97.8±27.9 88.4±29.9 86.3±25.7 82.1±23.8 
TC (mg/dL) 192±25.5* 155.9±22.1 149.9±20.9 136.76±23.7 
TG (mg/dL) 194.7±24.5* 145.8±23.8 148.8±24.5 139.3±23.1 
HDL-C (mg/dL) 45.5±25.2 43.8±22.8 43.6±23.4 44.4±21.5 
LDL-C (mg/dL) 155.6±23.9* 127.9±21.7 126.3±20.9 124.7±21.3 
Hemoglobin (g/dL) 11.4±6.9 12.7±7.4 11.7±5.8 11.3±6.7 
BMI: body mass index; MUAC: mid upper arm circumference; WC: waist circumference; WHR: Waist-to-Hip-Ratio; Sum SF: sum 
of skin folds; SBP: systolic blood pressure; DBP: diastolic blood pressure; HOMA-IR: homeostasis model assessment-insulin 
resistance; ALT: alanine aminotransferase; AST: aspartate aminotransferase; FPG: fasting plasma glucose; TC: total cholesterol; 
TG: triglycerides; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol 
*p value vs Q4<0.05 
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Table 3: Univariate and stepwise multiple regression analyses for determinants of sRAGE in obese 
cases 
Characteristics Univariate* Multivariate+ 
Factors β P β P 
BMI > 30 (kg/m2) -.39 .02 .29 .04 
MUAC .121 NS   
WC > 90 cm -.35 .01 .32 .01 
WHR -.29 NS   
SF .121 NS   
Fat % .121 NS   
Hypertension -.32 .01 .21 .01 
ALT -.41 .01 .32 .01 
AST -.36 .02 .33 .02 
FPG .109 NS   
HOMA-IR > 3.3 -3.99 .03 .35 .01 
TC .109 NS   
HDL-C .39 NS   
LDL-C .31 .02 -.22 .03 
TG -.38 .03 .31 .01 
HB .109 NS   
Adjusted R2 .399  .294  
β, regression coefficient; *Univariate coefficients; +A stepwise multivariate regression analysis; NS, not significant 
BMI: body mass index; MUAC: mid upper arm circumference; WC: waist circumference; WHR: Waist-to-Hip-Ratio; Sum SF: sum 
of skin folds; ALT: alanine aminotransferase; AST: aspartate aminotransferase; FPG: fasting plasma glucose; HOMA-IR: homeo-
stasis model assessment-insulin resistance; TC: total cholesterol; HDL-C: high density lipoprotein cholesterol; LDL-C: low density 
lipoprotein cholesterol; TG: triglycerides; HB: hemoglobin 
 
 
of the present study also are in agreement with 
the work of Basta et al. (2006) which showed 
that serum sRAGE concentrations were 
downregulated in insulin resistance status. 
Our study suggests that circulating endoge-
nous sRAGE levels may become a novel bi-
omarker of abnormal metabolic status and li-
pid metabolism in obese women. Previously, 
serum sRAGE levels have been proposed as 
biomarkers of severity or prognosis of several 
diseases, and modified by several factors, 
such as BMI, RAGE polymorphisms, kidney 
dysfunction and some medications such as 
statin (Maillard-Lefebvre et al., 2009). 
The lower levels of sRAGE in obese sub-
jects that have been noticed in our study were 
in agreement with the work of Brix and col-
leagues (2012), who observed lower levels in 
obese cases compared to controls and an in-
crease in sRAGE levels has been observed af-
ter bariatric surgery. Moreover, Vazzana and 
colleagues (2012) observed that sRAGE sig-
nificantly increases following diet-induced 
weight loss in obese women. However, an-
other study conducted by Lorenzi and col-
leagues (2014) showed contrast results, where 
higher levels of sRAGE have been reported in 
obese subjects and it went significantly lower 
after the gastric bypass surgery. They even 
suggested that restoring of several physiolog-
ical functions that associated with gastric by-
pass and decreasing the metabolic syndrome 
could also have contributed to the rapid elim-
ination of sRAGE of the body. It was sug-
gested that these controversial findings are 
due to the inclusion/exclusion criteria applied 
(Lorenzi et al., 2014). Bariatric surgery  has 
also been shown to promote a reduction in ox-
idized low-density lipoprotein (LDL) 
(Garrido-Sánchez et al., 2008). Lorenzi and 
colleagues (2014) have reported improve-
ments in the lipid profile, decreased LDL, in-
creased HDL and diabetes attenuation follow-
ing weight-loss surgery. It is well known that 
low HDL levels contribute substantially to 
higher vascular risk (Gordon et al., 1977).  
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The mechanism of interaction between 
sRAGE, obesity, and MS is not yet clear. As 
many ligands that interact with RAGE are im-
portant inflammatory regulators (Ueno et al., 
2010), it is likely that inflammation might be 
the linkage between sRAGE, obesity, and 
MS. A possible cellular mechanism for acti-
vating this inflammatory signaling has been 
suggested by  Shoelson et al. (2006). In addi-
tion, another study further illustrated that 
RAGE could modulate atherosclerosis via ad-
iposity and could be involved in the progres-
sion of atherosclerosis in non-diabetic status 
(Ueno et al., 2010). The recently higher prev-
alence of obesity is most probably a cause of 
the rising incidence of insulin resistance and 
MS, as well as CVD and type 2 diabetes. The 
possible role of sRAGE in the pathogenesis of 
obesity and MS has been shown in earlier life 
as well (He et al., 2014). However, a con-
trasting data regarding the relationship of 
sRAGE with CVD risk and disease has been 
reported. Some studies showed a positive re-
lationship between sRAGE and CVD in long-
term diabetes (type 1 and 2) (Selvin et al., 
2013). On the contrary, an inverse association 
between sRAGE and CVD risk has been de-
tected in general community-based cohorts 
(Hudson et al., 2011). Further clinical and bi-
ological studies are required in order to ex-
plore the cause of these contrasting results 
and whether the role of sRAGE as a bi-
omarker is affected by the presence of chronic 
disease such as diabetes. No influence of dia-
betes on the sRAGE levels has been reported 
though (Lorenzi et al., 2014). There is a pos-
sibility that other factors might affect sRAGE 
levels and cause these controversial results. In 
addition to metabolic components, race, eth-
nicity and kidney function, there are other fac-
tors such as age, smoking and some types of 
medication including anti-diabetic medica-
tion, statins, ACE inhibitors have been shown 
to affect sRAGE levels  (Tam et al., 2010) 
The present study showed that lower cir-
culating sRAGE concentrations may be asso-
ciated with higher prevalence of metabolic 
risk parameters and increasing the prevalence 
of central obesity, elevated BP, LDL and TG 
among Egyptian obese women. In addition, 
an inverse association between sRAGE level 
and liver enzymes (ALT and AST) has been 
observed as well. It was proposed that meta-
bolic syndrome might have non-traditional 
components such as subclinical inflamma-
tion, microalbuminuria, and non-alcoholic 
fatty liver disease (NAFLD) (Mulhall et al., 
2002; Adams et al., 2005). Some mechanisms 
have been suggested to illustrate the associa-
tions of ALT and AST-to-ALT ratio with the 
metabolic syndrome. One of these proposed 
mechanisms is that these markers have been 
found to be positively correlated with hepatic 
fat content and NAFLD has harmful effects 
on metabolic syndrome components 
(Browning et al., 2004). Hudson et al. (2014) 
conducted a multi-ethnic community-based 
study and showed that lower sRAGE levels 
are associated with metabolic syndrome and 
its components that related to obesity, diabe-
tes and hypertension. Although this associa-
tion varies by ethnicity, the study emphasized 
the role of RAGE as a risk factor for meta-
bolic and vascular disease (Hudson et al., 
2014). 
In conclusion, our data showed an associ-
ation between reduced sRAGE levels in obese 
subjects with high levels of lipid and meta-
bolic markers. This association could raise the 
possibility that, the measurement of sRAGE 
level may improve risk assessment among 
obese women. This study supports the poten-
tial role of sRAGE in the development of poor 
clinical outcomes in obese women and might 
predict future cardio-metabolic events. Future 
studies should examine whether these differ-
ences in sRAGE levels have an implication 
for asymptomatic obese subjects. 
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